Linus Health Showcases Digital Tools for Alzheimer's Clinical Trials at CTAD
核心洞察
Linus Health (搜索) is presenting four posters at CTAD demonstrating how its digital platform enhances Alzheimer's clinical trials.
The Digital Clock and Recall (搜索) (DCR) platform shows comparable accuracy to blood biomarkers in predicting cognitive impairment (搜索).
The electronic Person Specific Outcome Measure tool incorporates individual brain health priorities into clinical trial outcomes.
Linus Health (搜索), a digital health company focused on early detection of Alzheimer's and other dementias (搜索), is presenting four poster presentations at the Clinical Trials on Alzheimer's Disease (搜索) (CTAD) conference in Madrid, Spain. The presentations highlight how Linus Health's digital health platform streamlines clinical trials, enables precision recruitment, and delivers improved outcome assessments.
The CTAD conference brings together leading experts to discuss the latest therapeutic advances in Alzheimer's disease (搜索). Linus Health (搜索)'s contributions focus on leveraging technology to improve the efficiency and effectiveness of clinical trials.
Streamlining Recruitment with Digital Cognitive Assessment
One poster presentation, led by Ali Jannati, MD, PhD, Director of Cognitive Science at Linus Health (搜索), demonstrates that the Digital Clock and Recall (搜索)™ (DCR™) platform matches the accuracy of blood-based biomarkers in predicting cognitive impairment (搜索). The DCR's performance was also superior or comparable to traditional cognitive tests. These results suggest that DCR can effectively streamline recruitment for clinical trials, offering a cost-effective solution for selecting suitable participants and reducing screen failure rates.
Incorporating Personal Priorities in Clinical Trial Outcomes
Another study, led by Chief Medical Officer Alvaro Pascual-Leone, MD, PhD, explores the heterogeneity in individual-level brain health priorities in the United States. The findings indicate that self-reported confidence in managing personally meaningful priorities may be an appropriate construct to incorporate the person's voice in study outcomes. Linus Health (搜索)'s electronic Person Specific Outcome Measure tool supports the establishment of clinical meaningfulness in Alzheimer's disease (搜索) trials and is being validated in other global populations.
Enhancing Cognitive Impairment Screening with Speech and Drawing Analysis
Tanya Talkar, PhD, Data Scientist at Linus Health (搜索), is presenting a poster showcasing the benefits of combining speech- and linguistic-based metrics with drawing- and process-based metrics in screening for cognitive impairment (搜索). The screening can be administered both in the clinic and remotely, offering researchers accessible, repeated recordings to screen for clinical trials or evaluate disease-modifying therapies.
Optimizing Neuropsychology Workflow with Digital Assessment
Jannati is also presenting a study proposing a workflow involving a technology-enabled psychometry assistant (TPA), a medical assistant equipped with the Linus Health (搜索) Core Cognitive Evaluation (CCE) and Clinical Decision Support (CDS) system, to streamline the initial cognitive assessment process at the primary care level. The proposed workflow significantly improved the efficiency of neuropsychological evaluations by reducing the workload of specialists, avoiding unnecessary referrals, and prioritizing those that need further assessment.
"This honor certainly demonstrates the quality and relevancy of our research. It is also an indicator that the leaders in the field of Alzheimer's disease (搜索) and related dementias (搜索) recognize the growing value of augmenting human clinical expertise with innovative technology to deliver much broader insight into cognitive function with greater efficiency," said David Bates, PhD, CEO of Linus Health (搜索).